Cahill Represents Debt Financing Sources in $1.1 Billion of Debt Financings, Consisting of $650 Million Notes Offering and $450 Million Credit Facility for Catalent Pharma Solutions, Inc.
Date: 09/29/21
Cahill represented the lead arrangers in connection with a $450,000,000 incremental term B credit facility for Catalent Pharma Solutions, Inc. Cahill also represented the initial purchasers in connection with a Rule 144A offering of $650,000,000 aggregate principal amount of 3.500% senior notes due 2030 by Catalent Pharma Solutions, Inc. Proceeds from the incremental facility and the notes offering were used to finance the acquisition of Bettera Holdings, LLC and for general corporate purposes. Catalent develops and produces drug delivery systems.